Drug
Liraglutide Pen Injector [Saxenda]
Liraglutide Pen Injector [Saxenda] is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_4
1
25%
Ph phase_3
1
25%
Ph early_phase_1
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
Completed2
Suspended1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
completed250%
suspended125%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
suspendedearly_phase_1
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
NCT06171152
unknownnot_applicable
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
NCT05285397
completedphase_3
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
NCT03480022
completedphase_4
Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response
NCT03341429
Clinical Trials (4)
Showing 4 of 4 trials
NCT06171152Early Phase 1
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
NCT05285397Not Applicable
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
NCT03480022Phase 3
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
NCT03341429Phase 4
Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4